ConductScience.org, home

Paper41404698

Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.

Rizk DV and 5 others. Clin J Am Soc Nephrol, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics. Papers, record 41404698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41404698

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.
PubMed
Journal
Clin J Am Soc Nephrol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-09-22
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rizk DVDana V
2Dixon BPBradley Phttps://orcid.org/0000-0003-3704-0922
3Chan MMelvinhttps://orcid.org/0000-0002-6786-8336
4Cook HTH Terencehttps://orcid.org/0000-0002-8950-1041
5Frazer-Abel AAshley
6Tang SCWSydney C Whttps://orcid.org/0000-0002-6862-1941

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement System ProteinsMajor topic
Kidney DiseasesMajor topic
Complement ActivationMajor topic
Complement Inactivating AgentsMajor topic
Humans
Biomarkers
Predictive Value of Tests

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Novartis Pharmaceuticals CorporationPubMed

Source PubMed

Download CSV of grants

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138145741Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.Transplant Cell Ther2024https://conductscience.org/library/papers/38145741PubMed
240177195Research progress on the roles of complement in liver injury.World J Hepatol2025https://conductscience.org/library/papers/40177195PubMed
324578331Association of C4d deposition with clinical outcomes in IgA nephropathy.Clin J Am Soc Nephrol2014https://conductscience.org/library/papers/24578331PubMed
431477814Utility of immunohistochemistry with C3d in C3 glomerulopathy.Mod Pathol2020https://conductscience.org/library/papers/31477814PubMed
539455063Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.J Am Soc Nephrol2025https://conductscience.org/library/papers/39455063PubMed
637914086Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.Kidney Int2024https://conductscience.org/library/papers/37914086PubMed
734379175Complement activation in IgA nephropathy.Semin Immunopathol2021https://conductscience.org/library/papers/34379175PubMed
825877499Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus.J Rheumatol2015https://conductscience.org/library/papers/25877499PubMed
933962553Complement testing in the clinical laboratory.Crit Rev Clin Lab Sci2021https://conductscience.org/library/papers/33962553PubMed
1036404708Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.Am J Nephrol2022https://conductscience.org/library/papers/36404708PubMed
1130655025Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.Kidney Int2019https://conductscience.org/library/papers/30655025PubMed
1225780008Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers.Am J Clin Pathol2015https://conductscience.org/library/papers/25780008PubMed
1333841408Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival.Front Immunol2021https://conductscience.org/library/papers/33841408PubMed
1439803605Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy.Drug Des Devel Ther2025https://conductscience.org/library/papers/39803605PubMed
1533536243Inherited Kidney Complement Diseases.Clin J Am Soc Nephrol2021https://conductscience.org/library/papers/33536243PubMed
1629361307Renal tubule injury: a driving force toward chronic kidney disease.Kidney Int2018https://conductscience.org/library/papers/29361307PubMed
1737069992Proteomic Analysis of Complement Proteins in Glomerular Diseases.Kidney Int Rep2023https://conductscience.org/library/papers/37069992PubMed
1833568389Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.Lupus Sci Med2021https://conductscience.org/library/papers/33568389PubMed
1936161656With complements: C3 inhibition in the clinic.Immunol Rev2023https://conductscience.org/library/papers/36161656PubMed
207678717Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis.Am J Pathol1993https://conductscience.org/library/papers/7678717PubMed

See all 128 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42530828The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Adv Ther2026https://conductscience.org/library/papers/42530828PubMed
42387937Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?Eur J Immunol2026https://conductscience.org/library/papers/42387937PubMed
42303232Eculizumab for rapidly progressive glomerulonephritis in children.Nephrol Dial Transplant2026https://conductscience.org/library/papers/42303232PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41404698

GET https://conductscience.org/api/papers/v1/41404698/references?page=2